Cargando…

No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination

Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual’s previous encounter w...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Anders, Azimi, Linda, Tete, Sarah, Zhou, Fan, Krammer, Florian, Cox, Rebecca Jane, Jul-Larsen, Åsne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668305/
https://www.ncbi.nlm.nih.gov/pubmed/31384744
http://dx.doi.org/10.1016/j.jvacx.2019.100029
_version_ 1783440192808419328
author Madsen, Anders
Azimi, Linda
Tete, Sarah
Zhou, Fan
Krammer, Florian
Cox, Rebecca Jane
Jul-Larsen, Åsne
author_facet Madsen, Anders
Azimi, Linda
Tete, Sarah
Zhou, Fan
Krammer, Florian
Cox, Rebecca Jane
Jul-Larsen, Åsne
author_sort Madsen, Anders
collection PubMed
description Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual’s previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009. We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza.
format Online
Article
Text
id pubmed-6668305
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-66683052019-08-05 No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination Madsen, Anders Azimi, Linda Tete, Sarah Zhou, Fan Krammer, Florian Cox, Rebecca Jane Jul-Larsen, Åsne Vaccine X Regular paper Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual’s previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009. We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC). The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza. Elsevier 2019-06-20 /pmc/articles/PMC6668305/ /pubmed/31384744 http://dx.doi.org/10.1016/j.jvacx.2019.100029 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Regular paper
Madsen, Anders
Azimi, Linda
Tete, Sarah
Zhou, Fan
Krammer, Florian
Cox, Rebecca Jane
Jul-Larsen, Åsne
No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_full No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_fullStr No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_full_unstemmed No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_short No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_sort no evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
topic Regular paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668305/
https://www.ncbi.nlm.nih.gov/pubmed/31384744
http://dx.doi.org/10.1016/j.jvacx.2019.100029
work_keys_str_mv AT madsenanders noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT azimilinda noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT tetesarah noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT zhoufan noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT krammerflorian noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT coxrebeccajane noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT jullarsenasne noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination